|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fearon ER and Vogelsteine B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dienstmann R, Vermeulen L, Guinney J,
Kopetz S, Tejpar S and Tabernero J: Consensus molecular subtypes
and the evolution of precision medicine in colorectal cancer. Nat
Rev Cancer. 17:79–92. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Goldstein DA, Zeichner SB, Bartnik CM,
Neustadter E and Flowers CR: Metastatic colorectal cancer: A
systematic review of the value of current therapies. Clin
Colorectal Cancer. 15:1–6. 2016. View Article : Google Scholar :
|
|
5
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Manfredi S, Lepage C, Hatem C, Coatmeur O,
Faivre J and Bouvier AM: Epidemiology and management of liver
metastases from colorectal cancer. Ann Surg. 244:254–259. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Esteller M: Epigenetics in cancer. N Engl
J Med. 358:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Simó-Riudalbas L and Esteller M: Cancer
genomics identifies disrupted epigenetic genes. Hum Genet.
133:713–725. 2014. View Article : Google Scholar
|
|
10
|
Berg M and Søreide K: Genetic and
epigenetic traits as biomarkers in colorectal cancer. Int J Mol
Sci. 12:9426–9439. 2011. View Article : Google Scholar
|
|
11
|
Baylin SB and Jones PA: Epigenetic
determinants of cancer. Cold Spring Harb Perspect Biol. 8:pii:
a019505. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Feinberg AP: The key role of epigenetics
in human disease prevention and mitigation. N Engl J Med.
378:1323–1334. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miremadi A, Oestergaard MZ, Pharoah PD and
Caldas C: Cancer genetics of epigenetic genes. Hum Mol Genet.
16:R28–R49. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ferguson-Smith AC and Greally JM:
Epigenetics: Perceptive enzymes. Nature. 449:148–149. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Søreide K: Chapter 34 - Cancer Epigenetics
In: Handbook of Epigenetics. 2nd Edition. Academic Press; 2017
|
|
16
|
Nihira NT and Yoshida K: Engagement of
DYRK2 in proper control for cell division. Cell Cycle. 14:802–807.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Taira N, Nihira K, Yamaguchi T, Miki Y and
Yoshida K: DYRK2 is targeted to the nucleus and controls p53 via
Ser46 phosphorylation in the apoptotic response to DNA damage. Mol
Cell. 25:725–738. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yoshida K: Nuclear trafficking of
pro-apoptotic kinases in response to DNA damage. Trends Mol Med.
14:305–313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Taira N, Mimoto R, Kurata M, Yamaguchi T,
Kitagawa M, Miki Y and Yoshida K: DYRK2 priming phosphorylation of
c-Jun and c-Myc modulates cell cycle progression in human cancer
cells. J Clin Invest. 122:859–872. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maddika S and Chen J: Protein kinase DYRK2
is a scaffold that facilitates assembly of an E3 ligase. Nat Cell
Biol. 11:409–419. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jung HY, Wang X, Jun S and Park JI:
Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by
TERT degradation. J Biol Chem. 288:7252–7262. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mimoto R, Taira N, Takahashi H, Yamaguchi
T and Okabe M: DYRK2 controls the epithelial-mesenchymal transition
in breast cancer by degrading Snail. Cancer Lett. 339:214–225.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamashita S, Chujo M, Moroga T, Anami K,
Tokuishi K, Miyawaki M, Kawano Y, Takeno S, Yamamoto S and Kawahara
K: DYRK2 expression may be a predictive marker for chemotherapy in
non-small cell lung cancer. Anticancer Res. 29:2753–2757.
2009.PubMed/NCBI
|
|
24
|
Zhang X, Xu P, Ni W, Fan H, Xu J, Chen Y,
Huang W, Lu S, Liang L, Liu J, et al: Downregulated DYRK2
expression is associated with poor prognosis and Oxaliplatin
resistance in hepatocellular carcinoma. Pathol Res Pract.
212:162–170. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yan H, Hu K, Wu W, Li Y, Tian H, Chu Z,
Koeffler HP and Yin D: Low expression of dyrk2 (dual specificity
tyrosine phosphorylation regulated Kinase 2) correlates with poor
prognosis in colorectal cancer. PLoS One. 11:e01599542016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ito D, Yogosawa S, Mimoto R, Hirooka S,
Horiuchi T, Eto K, Yanaga K and Yoshida K: Dual-specificity
tyrosine-regulated kinase 2 is a suppressor and potential
prognostic marker for liver metastasis of colorectal cancer. Cancer
Sci. 108:1565–1573. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
28
|
Amin MB, Edge S, Greene F, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC Cancer Staging Manual. 8th edition.
Springer; New York: 2017, View Article : Google Scholar
|
|
29
|
Komashko VM and Farnham PJ: 5-azacytidine
treatment reorganizes genomic histone modification patterns.
Epigenetics. 5:229–240. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim M, Miyamoto S, Sugie S, Yasui Y,
Ishigamori-Suzuki R, Murakami A, Nakagama H and Tanaka T: A
tobacco-specific carcinogen, NNK, enhances AOM/DSS-induced colon
carcinogenesis in male A/J mice. In Vivo. 22:557–563.
2008.PubMed/NCBI
|
|
31
|
Tanaka T, Kohno H, Suzuki R, Yamada Y,
Sugie S and Mori H: A novel inflammation-related mouse colon
carcinogenesis model induced by azoxymethane and dextran sodium
sulfate. Cancer Sci. 94:965–973. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tanaka T, Yasui Y, Tanaka M, Tanaka T,
Oyama T and Rahman KM: Melatonin suppresses AOM/DSS-induced large
bowel oncogenesis in rats. Chem Biol Interact. 177:128–136. 2009.
View Article : Google Scholar
|
|
33
|
Yasui Y, Hosokawa M, Mikami N, Miyashita K
and Tanaka T: Dietary astaxanthin inhibits colitis and
colitis-associated colon carcinogenesis in mice via modulation of
the inflammatory cytokines. Chem Biol Interact. 193:79–87. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Miyoshi N, Nagasawa T, Mabuchi R, Yasui Y,
Wakabayashi K, Tanaka T and Ohshima H: Chemoprevention of
azoxymethane/dextran sodium sulfate-induced mouse colon
carcinogenesis by freeze-dried yam sanyaku and its constituent
diosgenin. Cancer Prev Res (Phila). 4:924–934. 2011. View Article : Google Scholar
|
|
35
|
Mimoto R, Imawari Y, Hirooka S, Takeyama H
and Yoshida K: Impairment of DYRK2 augments stem-like traits by
promoting KLF4 expression in breast cancer. Oncogene. 36:1862–1872.
2017. View Article : Google Scholar
|
|
36
|
Silverman LR, Demakos EP, Peterson BL,
Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D,
Powell BL, DeCastro CM, et al: Randomized controlled trial of
azacitidine in patients with the myelodysplastic syndrome: A study
of the cancer and leukemia group B. J Clin Oncol. 20:2429–2440.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gnyszka A, Jastrzebski Z and Flis S: DNA
methyltransferase inhibitors and their emerging role in epigenetic
therapy of cancer. Anticancer Res. 33:2989–2996. 2013.PubMed/NCBI
|
|
38
|
Tsai HC, Li H, Van Neste L, Cai Y, Robert
C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, et al:
Transient low doses of DNA-demethylating agents exert durable
antitumor effects on hematological and epithelial tumor cells.
Cancer Cell. 21:430–446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Probst AV, Dunleavy E and Almouzni G:
Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell
Biol. 10:192–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
He S, Wang F, Yang L, Guo C, Wan R, Ke A,
Xu L and Hu G: Expression of DNMT1 and DNMT3a are regulated by GLI1
in human pancreatic cancer. PLoS One. 6:e276842011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rajendran G, Shanmuganandam K, Bendre A,
Muzumdar D, Goel A and Shiras A: Epigenetic regulation of DNA
methyltransferases: DNMT1 and DNMT3B in gliomas. J Neurooncol.
104:483–494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mizuno S, Chijiwa T, Okamura T, Akashi K,
Fukumaki Y, Niho Y and Sasaki H: Expression of DNA
methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in
acute and chronic myelogenous leukemia. Blood. 97:1172–1179. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Robertson KD, Uzvolgyi E, Liang G,
Talmadge C, Sumegi J, Gonzales FA and Jones PA: The human DNA
methyltransferases (DNMTs) 1, 3a and 3b: Coordinate mRNA expression
in normal tissues and overexpression in tumors. Nucleic Acids Res.
27:2291–2298. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lee YC, Lee YL, Chuang JP and Lee JC:
Differences in survival between colon and rectal cancer from SEER
data. PLoS One. 8:e787092013. View Article : Google Scholar : PubMed/NCBI
|
